# Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

> **NCT00085839** · PHASE2 · COMPLETED · sponsor: **OSI Pharmaceuticals** · enrollment: 103 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Tarceva (Trademark) (erlotinib HCl, OSI-774)
- **DRUG:** Combination carboplatin and paclitaxel

## Key facts

- **NCT ID:** NCT00085839
- **Lead sponsor:** OSI Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2012-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00085839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00085839, "Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT00085839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*